Organogenesis Holdings Inc. (NASDAQ:ORGO) was the recipient of unusually large options trading on Thursday. Stock investors purchased 2,519 put options on the company. This is an increase of 1,284% compared to the average volume of 182 put options.
ORGO has been the topic of several recent analyst reports. Credit Suisse Group upped their price target on Organogenesis from $24.00 to $25.00 and gave the company an “outperform” rating in a research note on Tuesday, August 10th. SVB Leerink reaffirmed a “buy” rating on shares of Organogenesis in a research note on Monday, September 20th. BTIG Research initiated coverage on Organogenesis in a research note on Thursday, August 26th. They issued a “buy” rating and a $27.00 price target on the stock. Finally, Zacks Investment Research raised Organogenesis from a “hold” rating to a “buy” rating and set a $17.00 price target on the stock in a research note on Thursday, August 12th. Four analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $23.75.
In other Organogenesis news, CEO Gary S. Gillheeney sold 139,763 shares of the business’s stock in a transaction on Friday, July 16th. The stock was sold at an average price of $14.74, for a total transaction of $2,060,106.62. Following the transaction, the chief executive officer now owns 156,230 shares of the company’s stock, valued at $2,302,830.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Michael W. Katz acquired 12,000 shares of the stock in a transaction on Tuesday, August 17th. The shares were bought at an average cost of $13.55 per share, for a total transaction of $162,600.00. Following the purchase, the insider now directly owns 49,282 shares of the company’s stock, valued at approximately $667,771.10. The disclosure for this purchase can be found here. Insiders own 57.20% of the company’s stock.
Shares of NASDAQ:ORGO opened at $15.42 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.39 and a quick ratio of 2.05. The firm has a market capitalization of $1.98 billion, a PE ratio of 27.54 and a beta of 1.86. The firm’s 50-day moving average is $15.43 and its two-hundred day moving average is $17.29. Organogenesis has a 1 year low of $3.45 and a 1 year high of $24.34.
Organogenesis (NASDAQ:ORGO) last issued its quarterly earnings results on Monday, August 9th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.09. The company had revenue of $123.20 million for the quarter, compared to analyst estimates of $105.65 million. Organogenesis had a net margin of 16.17% and a return on equity of 51.16%. Analysts expect that Organogenesis will post 0.38 EPS for the current fiscal year.
Organogenesis Holdings, Inc is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.
Featured Article: 52-Week High/Low Prices For Stock Selection
Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.